FREDUN PHARMACEUTICALS L

Sells generic pharmaceutical formulations distributed in India and 52 international markets, alongside an expanding portfolio of consumer health products. The legacy generics business covers 1,200 products under registration, with 697 globally approved, and is supported by the Palghar manufacturing plant and 37 contract manufacturing sites; capacity expansion is underway across three plants plus one new plant. New-age verticals — pet care, nutrition, mobility, dermaceutics and cosmetics — are being built through acquisitions and own-brand launches, including One Pet Stop (4,000 recurring pet parents) and Wagr.ai (140,000 pet parents), and Snacky Jain functional pet food, with 12 tons already sold via preorders and the line now rolling out across six cities. FY26 consolidated total income reached Rs 633.33 cr, with EBITDA margin of 14.93%. Management targets new-age businesses to contribute 51% of revenue by FY29-30, and 51% of revenue from US operations by FY32. Materials account for 75.9% of revenue, the dominant cost line, while capex runs at 11.6% of revenue to fund capacity additions. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Legacy generic pharmaceuticals, Pet care, Nutrition / nutraceuticals, Mobility / orthopaedics, Dermaceuticals and cosmetics, Contract manufacturing. Diversified pharma plus consumer-health business; legacy generics funded cash generation, with asset-light scaling in pet care, nutrition, mobility and dermaceuticals.

Exhibit 1: Financial summary, FY25–FY26 (all audited; no estimate years)